What is meant by recent announcement by Dr. Reddy’s to Co-Develop Biosimilar Candidate for global markets... source: nsearchives.nseindia.com/cor… Deal Structure & Financials Partnership: Dr. Reddy's Alvotech for AVT03 (denosumab biosimilar) Investment: ₹560 crores ($67mn) - ₹317 crores upfront ₹243 crores milestones Revenue Share: Sales-based payments to Alvotech Rights: Exclusive US Semi-exclusive Europe/UK markets Market Opportunity TAM: $3.7bn (FY25) → $5.59bn (FY29) at 13% CAGR Reference Product: Prolia/Xgeva ($5.3bn revenue in 2021) Indication: Osteoporosis (postmenopausal women) cancer bone complications Strategic Rationale - Portfolio Upgrade: Shift from low-margin generics to high-value biosimilars US Market Entry: Exclusive access to world's largest pharma market - De-risked Model: Alvotech handles R&D/manufacturing; DRL leverages existing commercial infrastructure Recent Developments - Regulatory: FDA BLA accepted, EMA application filed - Clinical: Positive PK study results completed - Timeline: Commercial launch expected FY26-27 Financial Impact Revenue Potential: - ₹2,000-3,000 crores annually post-launch - Margin Accretion: Biosimilars command 30-40% higher margins vs generics - Payback: 3-4 years on ₹560 crore investment Key Risks - Regulatory approval delays - Pricing pressure from competition - Market penetration challenges Valuation & Recommendation - Current biosimilar portfolio contributes <10% to revenues. - Successful denosumab launch could add 15-20% to topline by FY28. screenshot from - alpha.8sapience.ai/ Disclaimer: Educational, DYOR, Consult Advisor